The 24th annual Ultimate Golf Experience brought together a standout array of entertainers, guests, and friends of the Cystic Fibrosis Foundation for a premier golfing event to raise funds in the fight against cystic fibrosis.
The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.
Tezacaftor/ivacaftor (Symdeko™) is approved for individuals with two copies of the most common cystic fibrosis mutation, F508del, as well as for individuals who have a single copy of one of 26 specified mutations -- regardless of their other mutation.
Today, the U.S. Food and Drug Administration approved the use of ivacaftor (Kalydeco®) for children with cystic fibrosis ages 1 to 2 who have at least one mutation that is responsive to ivacaftor.
Chad Riedy, an adult with cystic fibrosis, served as a witness on Wednesday before the House of Representatives' Education & Labor Committee at a hearing on the threats faced by workers with pre-existing conditions.
Vertex Pharmaceuticals Inc. announced today that it submitted a New Drug Application to the U.S. Food and Drug Administration for the approval of the first triple-combination therapy for cystic fibrosis.
Pam Baker and Justin Davis will lead this year's conference in San Diego.
One hundred fifty advocates, backed by more than 5,000 connections from an additional 1,600 cystic fibrosis advocates across the country rallied behind protections for people with pre-existing conditions, like CF, during the Cystic Fibrosis Foundation's 13th annual March on the Hill.